Blocking the ghrelin peptide receptor significantly reduced cannabinoid-triggered dopamine release in the brain's reward center, suggesting the hunger hormone system plays a key role in cannabis addiction processing.
Significant reduction in cannabinoid-induced dopamine effluxGHS-R1A (ghrelin receptor) antagonist pretreatment reduced the dopamine surge in the nucleus accumbens shell — the critical reward signal driving addiction processing
What the researchers found
Blocking the ghrelin receptor (GHS-R1A) with the antagonist JMV2959 significantly reduced cannabinoid-induced dopamine release in the nucleus accumbens shell — the brain's reward center and a critical trigger for addiction. JMV2959 pretreatment also attenuated cannabinoid-increased endocannabinoid levels (anandamide and 2-AG), reversed cannabinoid-induced GABA decreases, and reduced cannabinoid-triggered behavioral stimulation. This demonstrates that the ghrelin peptide system significantly participates in the rewarding and reinforcing effects of cannabinoids.
Why it matters
Cannabis addiction affects a growing number of people, and there are currently no approved pharmacological treatments. This study reveals that the ghrelin peptide signaling system is a key mediator of cannabinoid reward processing in the brain. Blocking the ghrelin receptor reduced the dopamine surge that drives addiction-related behaviors, suggesting that ghrelin receptor antagonists could become a novel treatment approach for cannabis use disorder.
The numbers in context
3 mg/kg JMV2959 (GHS-R1A antagonist) · Significant reduction in accumbens dopamine efflux · Attenuated anandamide and 2-AG increases · Reversed GABA decrease · Reduced behavioral stimulation
How the study worked
Preclinical study in male Wistar rats. The synthetic cannabinoid WIN55,212-2 was administered into the posterior ventral tegmental area (VTA) to trigger dopamine release. Rats were pretreated with the GHS-R1A antagonist JMV2959 (3 mg/kg i.p.) or vehicle. Dopamine, endocannabinoids (anandamide, 2-AG), and GABA levels in the nucleus accumbens shell were measured using microdialysis. Behavioral effects were assessed using LABORAS automated home cage monitoring.
Who was studied
Male Wistar rats in a preclinical study of ghrelin-cannabinoid reward interaction
What this study cannot tell us
This is an animal study using a synthetic cannabinoid agonist (WIN55,212-2) rather than THC, which may have different pharmacological properties. The study used a single dose of the ghrelin receptor antagonist and did not assess chronic treatment. Results in rats may not directly translate to human cannabinoid addiction. The ghrelin receptor antagonist JMV2959 is a research tool, not a clinical drug.
How to read the evidence
This is a preclinical animal study using a single synthetic cannabinoid and ghrelin receptor antagonist in rats. While the neurochemical and behavioral findings are clearly demonstrated, the translational relevance to human cannabis addiction requires further validation.
When this study was published
Published in 2020, this study contributes to the growing body of research on ghrelin's role in non-food reward processing. The field of ghrelin receptor-targeted therapies for addiction is still in early preclinical stages.
The bigger picture
The intersection of the ghrelin peptide system and cannabinoid reward processing connects two important areas: appetite regulation and substance abuse. Both systems overlap in brain regions controlling food intake (hypothalamus) and reward (VTA, nucleus accumbens). This cross-talk may explain why cannabis use increases appetite ('the munchies') and suggests that ghrelin receptor antagonists could have therapeutic applications in substance use disorders — potentially extending beyond cannabis to other drugs of abuse.
Questions still open
- Would ghrelin receptor antagonists reduce cannabis-seeking behavior and relapse in chronic exposure models?
- Does the ghrelin-cannabinoid reward interaction also apply to THC, the primary psychoactive component of cannabis?
- Could ghrelin receptor antagonists treat cannabis use disorder without significantly affecting normal appetite and metabolism?
Common questions
What does ghrelin have to do with cannabis addiction?
Could a ghrelin-blocking drug help people quit cannabis?
Read the original research
Alterations in Rat Accumbens Dopamine, Endocannabinoids and GABA Content During WIN55,212-2 Treatment: The Role of Ghrelin.
International journal of molecular sciences, 22(1)
Citation
Charalambous, Chrysostomos; Lapka, Marek; Havlickova, Tereza; Syslova, Kamila; Sustkova-Fiserova, Magdalena. (2020). Alterations in Rat Accumbens Dopamine, Endocannabinoids and GABA Content During WIN55,212-2 Treatment: The Role of Ghrelin.. International journal of molecular sciences, 22(1). https://doi.org/10.3390/ijms22010210